Suppr超能文献

通过比较表达增强型绿色荧光蛋白或EGFP-荧光素酶融合基因的重组硕大利什曼原虫与野生型寄生虫的药物敏感性进行体外感染性评估。

In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.

作者信息

Sadeghi Somayeh, Seyed Negar, Etemadzadeh Mohammad-Hossein, Abediankenari Saeid, Rafati Sima, Taheri Tahereh

机构信息

Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.

Immunogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

出版信息

Korean J Parasitol. 2015 Aug;53(4):385-94. doi: 10.3347/kjp.2015.53.4.385. Epub 2015 Aug 25.

Abstract

Leishmaniasis is a worldwide uncontrolled parasitic disease due to the lack of effective drug and vaccine. To speed up effective drug development, we need powerful methods to rapidly assess drug effectiveness against the intracellular form of Leishmania in high throughput assays. Reporter gene technology has proven to be an excellent tool for drug screening in vitro. The effects of reporter proteins on parasite infectivity should be identified both in vitro and in vivo. In this research, we initially compared the infectivity rate of recombinant Leishmania major expressing stably enhanced green fluorescent protein (EGFP) alone or EGFP-luciferase (EGFP-LUC) with the wild-type strain. Next, we evaluated the sensitivity of these parasites to amphotericin B (AmB) as a standard drug in 2 parasitic phases, promastigote and amastigote. This comparison was made by MTT and nitric oxide (NO) assay and by quantifying the specific signals derived from reporter genes like EGFP intensity and luciferase activity. To study the amastigote form, both B10R and THP-1 macrophage cell lines were infected in the stationary phase and were exposed to AmB at different time points. Our results clearly revealed that the 3 parasite lines had similar in vitro infectivity rates with comparable parasite-induced levels of NO following interferon-γ/lipopolysaccharide induction. Based on our results we proposed the more reporter gene, the faster and more sensitive evaluation of the drug efficiency.

摘要

利什曼病是一种因缺乏有效药物和疫苗而在全球范围内无法控制的寄生虫病。为了加速有效药物的研发,我们需要强大的方法来在高通量检测中快速评估药物对利什曼原虫胞内形式的有效性。报告基因技术已被证明是体外药物筛选的优秀工具。应在体外和体内确定报告蛋白对寄生虫感染性的影响。在本研究中,我们首先比较了单独稳定表达增强型绿色荧光蛋白(EGFP)或EGFP-荧光素酶(EGFP-LUC)的重组硕大利什曼原虫与野生型菌株的感染率。接下来,我们评估了这些寄生虫在无鞭毛体和前鞭毛体这两个寄生阶段对作为标准药物的两性霉素B(AmB)的敏感性。通过MTT和一氧化氮(NO)检测以及通过量化来自报告基因的特定信号,如EGFP强度和荧光素酶活性进行了这种比较。为了研究无鞭毛体形式,B10R和THP-1巨噬细胞系在静止期被感染,并在不同时间点暴露于AmB。我们的结果清楚地表明,这3种寄生虫系具有相似的体外感染率,在干扰素-γ/脂多糖诱导后,寄生虫诱导的NO水平相当。基于我们的结果,我们提出报告基因越多,对药物效率的评估就越快且越敏感。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed2/4566512/275612658ba8/kjp-53-4-385f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验